<DOC>
	<DOCNO>NCT01369303</DOCNO>
	<brief_summary>The purpose study obtain data pharmacokinetics ( PK ) pharmacodynamics ( PD ) immune system effect BAT24 dose regimen versus daily pericoital dosing regimen vaginal use tenofovir 1 % gel single sex act multiple sex act .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Tenofovir 1 % Gel</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 1850 year , inclusive ; General good health ( volunteer history per investigator discretion ) without clinically significant systemic disease ( include , limited , significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , type 2 diabetes ) ; Currently regular menstrual cycle , hormonal ( include continuous ) contraception , volunteer report per investigator discretion ; History Pap smear followup consistent American Congress Obstetricians Gynecologist ( ACOG ) practice guideline # 109 ( see study manual ) willing undergo Pap smear Visit 1 . ( Note : See study manual clarification eligibility criterion specific Pap smear result . ) Willing abstain use vaginal product study gel include spermicide , lubricant , vaginal hygiene product , contraceptive intravaginal ring , diaphragm , cervical cap ( nonhormonal IUC use method contraception , allow ) duration study ; In monogamous relationship least last four month male partner , least 18 year old known risk STIs , know HIV positive , willing able comply study requirement , condom typically use ; Protected pregnancy sterilization either partner , use combination oral contraceptive patch least two cycle , nonhormonal intrauterine contraception throughout study . Continuous oral contraceptive allowable patient low risk breakthrough bleeding ; Vaginal cervical anatomy , opinion investigator , lend easy genital tract sample collection ; Negative urine pregnancy test ; Willing give voluntary consent , sign inform consent form comply study procedure require protocol . History hysterectomy ; Currently pregnant within two calendar month last pregnancy outcome . Note : If recently pregnant must least two spontaneous menses since pregnancy outcome ; Use DepoProvera last 120 day ; Currently breastfeed breastfed infant last two month , plan breastfeed course study ; History sensitivity/allergy component study product , topical anesthetic , allergy silver nitrate Monsel 's solution ; In last six month , diagnose treat STI pelvic inflammatory disease . Note : Women history genital herpes condylomata asymptomatic least six month may consider eligibility ; Symptomatic vulvovaginal candidiasis , Nugent score great equal 7 screen symptomatic bacterial vaginosis ( BV ) Visit 2 , symptomatic urinary tract infection ( UTI ) ; Positive test Trichomonas vaginalis , Neisseria gonorrhea Chlamydia trachomatis ; Deep epithelial genital finding abrasion , ulceration , laceration , vesicle suspicious sexually transmitted infection ; Positive test HIV ; Positive test Hepatitis B surface antigen ( HBsAg ) ; Known bleeding disorder could lead prolonged continuous bleed biopsy ; Chronic acute vulvar vaginal symptom ( pain , irritation , spot , etc . ) ; Known current drug alcohol abuse could impact study compliance ; Grade 1 high laboratory abnormality , per August 2009 update DAIDS Table Grading Severity Adverse Events ; Systemic use last two week anticipate use study drug daily basis may reduce renal function ( e.g. , ibuprofen ) liver function ( e.g. , Tylenol® ) , may affect antiHSV activity ( e.g. , acyclovir valacyclovir ) following : corticosteroid , antibiotic , antifungal , antiviral ( e.g . acyclovir valacylovir ) antiretrovirals ( e.g . Viread® ) . Note : Participants avoid nonsteroidal antiinflammatory drug ( NSAIDs ) except treatment dysmenorrhea menses . Participants may use Tylenol® asneeded daily basis study Participation investigational trial ( device , drug , vaginal trial ) within last 30 day study plan participation investigational trial study ; History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix within last 14 day ; Abnormal find laboratory physical examination social medical condition , opinion investigator , would make participation study unsafe would complicate interpretation data .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>HIV</keyword>
</DOC>